MYC and neoplasm: Moreover, among the four major subgroups of MB, tumor recurrence due to survival of therapy-resistant cells in the residual tumor is more frequently observed in SHH MB and MYC-driven group 3 MB patients and, therefore, remains a major clinical challenge for MB treatment.